Pages that link to "Q34119834"
Jump to navigation
Jump to search
The following pages link to GSK3 is a regulator of RAR-mediated differentiation (Q34119834):
Displaying 20 items.
- Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance (Q26829987) (← links)
- The role of TLR8 signaling in acute myeloid leukemia differentiation (Q35288072) (← links)
- Repression of GSK3 restores NK cell cytotoxicity in AML patients (Q36768725) (← links)
- A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity (Q37075360) (← links)
- Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation (Q37103762) (← links)
- Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. (Q37460101) (← links)
- RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells (Q37564753) (← links)
- An ATRActive future for differentiation therapy in AML. (Q38336112) (← links)
- Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells (Q38730327) (← links)
- GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation (Q41461266) (← links)
- Retinoid differentiation therapy for common types of acute myeloid leukemia (Q41723841) (← links)
- High constitutive Akt2 activity in U937 promonocytes: effective reduction of Akt2 phosphorylation by the histamine H2-receptor and the β2-adrenergic receptor (Q46652753) (← links)
- Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. (Q52668632) (← links)
- Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent. (Q54263446) (← links)
- Aberrant GSK3β nuclear localization promotes AML growth and drug resistance (Q58554216) (← links)
- Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML (Q58617350) (← links)
- Biomodulatory Treatment With Azacitidine, All- Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis (Q59807289) (← links)
- Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia (Q90642732) (← links)
- The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma (Q92644639) (← links)
- Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses (Q93034488) (← links)